Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival-Reference-Cited by-同舟云学术

Pseudomonas aeruginosa infection correlates with high MFI donor-specific antibody development following lung transplantation with consequential graft loss and shortened CLAD-free survival

Published:2024-07-01 Issue:1 Volume:25 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Bogyó Levente Zoltán,Török Klára,Illés Zsuzsanna,Szilvási Anikó,Székely Bálint,Bohács Anikó,Pipek Orsolya,Madurka Ildikó,Megyesfalvi Zsolt,Rényi-Vámos Ferenc,Döme Balázs,Bogos Krisztina,Gieszer Balázs,Bakos Eszter

Abstract

Abstract Background Donor-specific antibodies (DSAs) are common following lung transplantation (LuTx), yet their role in graft damage is inconclusive. Mean fluorescent intensity (MFI) is the main read-out of DSA diagnostics; however its value is often disregarded when analyzing unwanted post-transplant outcomes such as graft loss or chronic lung allograft dysfunction (CLAD). Here we aim to evaluate an MFI stratification method in these outcomes. Methods A cohort of 87 LuTx recipients has been analyzed, in which a cutoff of 8000 MFI has been determined for high MFI based on clinically relevant data. Accordingly, recipients were divided into DSA-negative, DSA-low and DSA-high subgroups. Both graft survival and CLAD-free survival were evaluated. Among factors that may contribute to DSA development we analyzed Pseudomonas aeruginosa (P. aeruginosa) infection in bronchoalveolar lavage (BAL) specimens. Results High MFI DSAs contributed to clinical antibody-mediated rejection (AMR) and were associated with significantly worse graft (HR: 5.77, p < 0.0001) and CLAD-free survival (HR: 6.47, p = 0.019) compared to low or negative MFI DSA levels. Analysis of BAL specimens revealed a strong correlation between DSA status, P. aeruginosa infection and BAL neutrophilia. DSA-high status and clinical AMR were both independent prognosticators for decreased graft and CLAD-free survival in our multivariate Cox-regression models, whereas BAL neutrophilia was associated with worse graft survival. Conclusions P. aeruginosa infection rates are elevated in recipients with a strong DSA response. Our results indicate that the simultaneous interpretation of MFI values and BAL neutrophilia is a feasible approach for risk evaluation and may help clinicians when to initiate DSA desensitization therapy, as early intervention could improve prognosis.

Funder

Semmelweis University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12931-024-02868-1.pdf

Reference47 articles.

1. Young KA, Ali HA, Beermann KJ, Reynolds JM, Snyder LD. Lung transplantation and the era of the Sensitized patient. Front Immunol. 2021;12:689420. https://doi.org/10.3389/fimmu.2021.689420.

2. Chambers DC, Perch M, Zuckermann A, et al. The international thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report – 2021; focus on recipient characteristics. J Heart Lung Transpl Oct. 2021;40(10):1060–72. https://doi.org/10.1016/j.healun.2021.07.021.

3. Loupy A, Lefaucheur C. Antibody-mediated rejection of Solid-Organ Allografts. N Engl J Med Sep. 2018;20(12):1150–60. https://doi.org/10.1056/NEJMra1802677.

4. Glanville AR, Verleden GM, Todd JL, et al. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transpl May. 2019;38(5):483–92. https://doi.org/10.1016/j.healun.2019.03.008.

5. Tissot A, Danger R, Claustre J, Magnan A, Brouard S. Early identification of chronic lung allograft dysfunction: the need of biomarkers. Front Immunol. 2019;10:1681. https://doi.org/10.3389/fimmu.2019.01681.